UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 15, 2015


EXACTECH, INC.

(Exact Name of Registrant as Specified in Its Charter)

Florida
0-28240
59-2603930
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

2320 NW 66th Court
Gainesville, Florida 32653
(Address of Principal Executive Office)

Registrant’s telephone number, including area code (352) 377-1140


(Former Name or Former Address, if Changed Since Last Report)

__________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR     240.14d-2(b))

[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR     240.13e-4(c))







Item 7.01. Regulation FD Disclosure.

On January 20, 2015, Exactech, Inc., a Florida corporation (the “Company”), issued a press release announcing the Company’s acquisition of France-based BlueOrtho SAS, the computer-assisted surgical technology development and manufacturing firm that partnered with the Company to develop the ExactechGPS® Guided Personalized Surgery system. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference in this Item 7.01.

The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, shall be deemed “furnished” and not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended.

The press release attached as an exhibit to this report contains various “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company’s expectations or beliefs concerning future events, including, but not limited to, statements regarding levels of and expected growth in sales of the Company’s products. When used in the press release and this report, the terms “anticipate,” “believe,” “estimate,” “expect” and “intend” and words or phrases of similar import, as they relate to the Company or its subsidiaries or its management, are intended to identify forward-looking statements. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the expansion into other segments of the Company, significant advancement in technology that improves patient outcomes, market acceptance of the Company’s products, the availability of third-party reimbursement for the Company’s products, the Company’s ability to protect its intellectual property, dedication of substantial resources towards research and development efforts, product liability risks and the effects of governmental regulation. Results actually achieved may differ materially from expected results included in these statements as a result of these or other factors, including those factors discussed under “Risk Factors” set forth in Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. The Company undertakes no obligation to update, and the Company does not have a policy of updating or revising, these forward-looking statements. The information in this report will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD. The furnishing of this information is not intended to, and does not, constitute a determination or admission by the Company that such information is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

Item 8.01.    Other Events.
On January 15, 2015, the Company completed its acquisition of 100% of the outstanding shares of BlueOrtho SAS, a France-based company. Blue Ortho is the computer-assisted surgical technology development and manufacturing firm that partnered with the Company to develop the ExactechGPS® Guided Personalized Surgery system. The aggregate purchase price for BlueOrtho is equal to a maximum of €10.0 million, of which €2.0 million was paid to the Blue Ortho shareholders in cash, and the remainder will be paid to such shareholders contingent on the achievement of certain milestones.

Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
Description
99.1
Press Release issued by the Company on January 20, 2015.









SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXACTECH, INC.
      
Date:
January 20, 2015
 
By:
/s/ Joel C. Phillips
 
 
 
 
Joel C. Phillips
 
 
 
 
Chief Financial Officer







EXHIBIT INDEX
Exhibit Number
Description
99.1
Press Release issued by the Company on January 20, 2015






EXHIBIT 99.1



Exactech Acquires Industry-Leading
Computer-Assisted Surgical Technology Company
 
Exactech Enhances R&D Competencies, Secures Exclusive Technology for ExactechGPS®-- Guided Personalized Surgery System

Gainesville, Fla. - January 20, 2015 - Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today the acquisition of an industry-leading computer-assisted surgical technology development and manufacturing firm, Grenoble France-based BlueOrtho SAS.

Exactech has partnered with BlueOrtho since 2009 to develop ExactechGPS® Guided Personalized Surgery system, which was introduced by Exactech in 2010 and fully commercialized in 2014. ExactechGPS currently supports Exactech’s comprehensive knee systems with plans to expand its application to other segments of the company’s portfolio.

According to Exactech Vice President of Engineering and Development for Large Joints Xavier Sarabia, “This acquisition is a logical next step in our partnership with BlueOrtho. Exactech is strategically invested in this technology because we believe it will become the new standard of patient care in total joint arthroplasty. BlueOrtho is a very talented, highly motivated group of professionals who work well with our staff. By welcoming them officially to the Exactech team, we broaden our engineering competencies to benefit our planned future developments.”

BlueOrtho was founded by President and CEO Anthony Boyer, orthopaedic surgeon James Stiehl, MD, and Dr. Stephane Lavallee Ph.D., a pioneer in the field of computer assisted surgery. According to Boyer, “The goal of the partnership between BlueOrtho and Exactech has been to develop a significant advancement in technology that improves patient outcomes. Exactech has been an ideal partner, due to their expertise in mechanical instrument design and their understanding of clinical issues related to patient outcomes. We are enthusiastic to build upon this success under the new structure.”

According to the terms of the agreement, Exactech will pay up to 10 million Euros for the 100% share acquisition with 2 million Euros paid at the closing on January 15, 2015 and a potential earnout amount of up to 8 million Euros based on the achievement of surgical case milestones using the technology. ExactechGPS is an advanced surgical technology that provides orthopaedic surgeons real-time visual guidance and alignment data in total joint arthroplasty. The system

--MORE--
EXACTECH INC.
Page 1 of 2




features a touch screen and proprietary camera system within the sterile field, the only of its kind on the market. Patients around the world have benefited from ExactechGPS. Through mechanical testing, the technology has demonstrated a high level of accuracy and precision.

About Exactech
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.


This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.


Investor contacts                        Julie Marshall or Frank Hawkins
Jody Phillips                             Hawk Associates
Chief Financial Officer                    305-451-1888
352-377-1140                        E-mail: exactech@hawkassociates.com


Media contact
Priscilla Bennett
Director Marketing Communication & Public Relations
352-377-1140






*****
EXACTECH INC.
Page 2 of 2

Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Exactech, Inc. (delisted) Charts.
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Exactech, Inc. (delisted) Charts.